Page 2 - Hematologic Malignancies Program News Today

PHILADELPHIA, Jan. 4, 2022 /PRNewswire/ -- Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Credit: CincyTech Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors. "We are excited to have the support of exceptional investors. This f...

The company is developing multiple formulation candidates in its STAR-LLD program into non-clinical studies

- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments -

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights News provided by Share this article - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On track to report clinical biomarker and safety data in breast cancer in 2021 - Strong financial foundation with approximately $50 million in cash on hand and cash runway to H2 2022 - Management hosting conference call and webcast today at 8:30 am ET SAN DIEGO...

Reducing Infectious Diarrhea in Organ Transplant and Leukemia Patients by Pooja Shete on  December 10, 2020 at 1:00 PM The most common form of infectious diarrhea in hospitalized patients is caused by bacteria Clostridium difficile. Clostridium difficile infection (CDI) results in inflammation of the colon. The most vulnerable population to develop CDI are those patients undergoing blood and bone marrow transplant (BMT) due to their prolonged hospitalization and previous expo...